OncoKB™ is a precision oncology knowledge base developed at Memorial Sloan Kettering Cancer Center that contains biological and clinical information about genomic alterations in cancer.
OnCo: the open, cited map of cancer: treatments, targets, trials, and what is coming
The open, cited map of oncology: every cancer, treatment, target, trial, company, institution and idea on one page each, in plain English first, with…
Sid Sijbrandij's Osteosarcoma Data
Explore Sid Sijbrandij's osteosarcoma research data: single-cell transcriptomics, tissue imaging, cell clusters, and gene set enrichment analysis from his own tumor samples.
RFK Jr. to Allow Broad Use of Unapproved Peptide Injections
In a unilateral declaration by the health secretary, several injections promoted by online influencers will become widely available. The F.D.A. had advised against the move.
Things that Apparently Cause Cancer
What does this methodology measure anyway?
Fred Hutch researchers test privacy-first AI platform for cancer research
Researchers at Fred Hutch Cancer Center are testing whether a collaborative AI research platform can accelerate the pace of cancer research leading to faster diagnoses and more precise, targeted therapies, especially for rare types of cancers while safeguarding patient privacy.
$250 million, 300 scientists and 40 labs: Sean Parker’s revolutionary project to ‘solve’ cancer
The collaboration, which will be formally announced Wednesday, focuses on immunotherapy -- an area of research that many believe represents the future of cancer treatment.
Biohub releases a world model of protein biology
Open AI models used for a wide range of scientific applications, including accelerating the design of therapeutic molecules.
AI for Drug Discovery Needs Trustworthy Biological Data
To unleash the potential of AI in life sciences and drug discovery, biological datasets must be authenticated, validated, and supported by standardized metadata.
Fighting Cancer - Hintjens.com
Biography | Portfolio | GitHub Books | Videos | Slides | Stories | Wiki Contact
Jude Gomila on Twitter / X
I've attempted to map everything in oncology in a public website and open source repo for all. The site is trying to get all cancers, products, technologies, bottlenecks, people, startup opportunities with 1000+ ideas for upgrading the field. If you have a loved one with… pic.twitter.com/ff5Bdss5BT— Jude Gomila (@judegomila) September 16, 2026
CIViC - Clinical Interpretation of Variants in Cancer
Hierarchical classification of immune cell transcriptomes at population-scale
Accurate immune cell classification is essential for interpreting single-cell RNA sequencing (scRNA-seq) data. However, progress is constrained by the lack of independent, high-resolution benchmarks, as the routine integration of datasets introduces statistical dependencies that artificially inflate model generalizability. Here, we present the single-cell universal classification omnibus (Suco), a resource of independent, uniform expert annotations, and Compocyte, a modular hierarchical classifier. Together, they establish a framework designed for the scale of human population immunology. This approach substantially outperforms existing classifiers while facilitating expert review of ambiguous annotations. Applying Compocyte across 50 studies, including three newly generated datasets, we classified 15.6 million leukocytes from 3,965 patients. Within this expansive cohort, we identified a new tumor-associated resorptive macrophage phenotype, a non-canonical monocyte subtype in subclinical cytokine release syndrome, and the programmatic erosion of T cell memory stemness across metastatic sites. Suco and Compocyte thus provide a generalizable architecture and benchmark capable of sustaining high-resolution annotation across massive clinical cohorts. ### Competing Interest Statement CMR has consulted regarding oncology drug development with Amgen, AstraZeneca, Daiichi Sankyo, Genentech, Merck, and Novartis, and has received licensing and royalty payments for DLL3-directed therapeutics. T.W. reports stock ownership for Roche, Astra Zeneca, Bayer, Innate Pharma, Kyntra, Illumina, 10x Genomics, and Merck KGaA as well as research funding from Atrandi Biosciences, Vilnius, Lithuania; CanVirex AG, Basel Switzerland; and Institut fuer Klinische Krebsforschung GmbH, Frankfurt, Germany, and travel funding from Roche, Basel, Switzerland. S.Z. reports advisory board membership and honoraria from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, EUSA, Gilead, Ipsen, Johnson&Johnson, Lilly, MedSir, Medtoday, Merck, MSD, Novartis, Pfizer, Roche, Sanofi Aventis, StreamedUp, Urotrials, Urotube, Zentiva and resarch funding from Eisai. S.Z. reports clinical trial support from Amgen, AstraZeneca, AVEO, Bayer, Biontech, Bristol-Myers Squibb, Calithera, Exelixis, Gilead, Lilly, MSD, Novartis, Pfizer, Roche, Seagen/Astellas, Urotrials and travels & conference support from Amgen, Astellas, AstraZeneca, Bayer, EISAI, Ipsen, Johnson&Johnson, Merck, MSD, Pfizer. All remaining authors declare no relevant competing interests. Spanish Association Against Cancer, PI049999 Federal Ministry of Research, Technology and Space, 001001KT2322 National Cancer Institute, R35 CA263816 National Cancer Institute, U24 CA213274 National Cancer Institute, P30 CA008748 Research Council of Lithuania, P-MIP-24-93
Open Science Community & Research Platform
ResearchHub is a collaborative platform for sharing, reviewing, and funding scientific research. Join the open science community.
Karpathy shares 'LLM Knowledge Base' architecture that bypasses RAG with an evolving markdown library maintained by AI
Karpathy proposes something simpler and more loosely, messily elegant than the typical enterprise solution of a vector database and RAG pipeline.
Paperclip
Paperclip — search, read, and analyze 11M+ biomedical papers, regulatory documents, clinical trials, and biological databases (UniProt, PDB, ChEMBL) from the command line.